BTK and atrial fibrillation: On the other hand, the higher risk of any‐grade bleeding seen with ibrutinib compared with acalabrutinib or zanubrutinib in the ELEVATE RR and ASPEN trials [12, 29], could potentially be explained by off‐target effects in platelets such as inhibition of SFK or BTK homologues TEC and BMX [35], differential effects on the conformational state of BTK [36], or increased anticoagulant usage due to a higher rate of AF/flutter in patients receiving ibrutinib compared to the more selective BTK inhibitors [37].